Combining fruquintinib with TAS-102 as a promising strategy: antitumor activity in preclinical colorectal and gastric cancer xenograft models
Takahito Hara(Takeda (Japan)), Takayuki Yoshino(University of Tsukuba), Junpei Soeda(Takeda (Japan)), Tsuyoshi Osaka(Takeda (Japan)), Hideaki Bando(Aichi Cancer Center), Megumi Morimoto(Takeda (Japan)), Momoko Kamedani(Takeda (Japan)), Masaaki Kakehi(Takeda (Japan)), Syunsuke Yamamoto(Takeda (Japan)), Miyu Nakayama(Takeda (Japan))
Cited by 0
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k